$1.91
4.37% yesterday
Nasdaq, May 20, 10:14 pm CET
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Iovance Biotherapeutics Inc Stock price

$1.91
-1.17 37.99% 1M
-6.23 76.54% 6M
-5.49 74.19% YTD
-8.44 81.55% 1Y
-13.52 87.62% 3Y
-35.34 94.87% 5Y
-8.83 82.22% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.08 4.37%
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Key metrics

Market capitalization $637.81m
Enterprise Value $331.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.56
P/S ratio (TTM) P/S ratio 3.00
P/B ratio (TTM) P/B ratio 0.83
Revenue growth (TTM) Revenue growth 11,070.12%
Revenue (TTM) Revenue $212.68m
EBIT (operating result TTM) EBIT $-398.78m
Free Cash Flow (TTM) Free Cash Flow $-347.50m
Cash position $360.27m
EPS (TTM) EPS $-1.23
P/E forward negative
P/S forward 2.23
EV/Sales forward 1.16
Short interest 24.46%
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Iovance Biotherapeutics Inc forecast:

8x Buy
62%
5x Hold
38%

Analyst Opinions

13 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
62%
Hold
38%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
213 213
11,094% 11,094%
100%
- Direct Costs 189 189
323% 323%
89%
23 23
155% 155%
11%
- Selling and Administrative Expenses 98 98
113% 113%
46%
- Research and Development Expense 279 279
18% 18%
131%
-354 -354
18% 18%
-166%
- Depreciation and Amortization 45 45
20% 20%
21%
EBIT (Operating Income) EBIT -399 -399
15% 15%
-188%
Net Profit -375 -375
17% 17%
-176%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Neutral
The Motley Fool
about 3 hours ago
Entering trading this week, shares of Iovance Biotherapeutics (IOVA 4.10%) have crashed by nearly 78% since the start of the year. It has been an abysmal start to 2025 for a company that does possess some attractive long-term growth prospects.
Neutral
Business Wire
about 12 hours ago
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED ...
Neutral
PRNewsWire
one day ago
NEW YORK , May 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 838
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today